This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Phosphoinositide 3-kinase- β (PI3K β); PTEN (MMAC1; TEP1)	A study in mice identified PI3K β -selective inhibitors that could help treat PTEN-deficient cancers. In a mouse xenograft model of PTEN-deficient prostate cancer, benzimidazole-pyrimidone-based and benzoxazole-pyrimidone-based PI3K β inhibitors decreased tumor growth compared with vehicle. Next steps could include testing the inhibitors in other models of PTEN-deficient cancers.	Patent and licensing status unavailable	Certal, V. <i>et al. J. Med. Chem.</i> ; published online April 23, 2012; doi:10.1021/jm300241b Contact: Frank Halley, Sanofi Research & Development, Vitry-sur-Seine, France e-mail: frank.halley@sanofi.com
<i>SciBX</i> 5(20); doi:10.1038/scibx.2012.516 Published online May 17, 2012				